Fulcrum Equity Partners leads investment round, along with Bee Partners and Atrium Health, to support Florence creating a new type of research network that speeds progress. ATLANTA, Oct. 10, 2019 /PRNewswire/ — Florence, an Atlanta-based clinical trials software...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to prevent neurotoxicity in patients with relapsed or refractory diffuse large B-cell...
Successful completion of Phase 2 monotherapy trial paves way for Phase 3 trials in China in early 2020 CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SHANGHAI–(BUSINESS WIRE)–Sixth paragraph, second sentence should read: “DED is more...
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with...
WOBURN, Mass.–(BUSINESS WIRE)–Frequency Therapeutics (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that...
Email
Text